Eli Lilly and Co., of Indianapolis, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, gained tentative FDA approval for their basal insulin, Basaglar (insulin glargine), to treat adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.